Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5104833 | Value in Health | 2016 | 11 Pages |
Abstract
Most currently available COPD cost-effectiveness models are able to evaluate the cost-effectiveness of personalized treatment on the basis of sex, age, smoking, and FEV1% predicted. Treatment in COPD is, however, more likely to be personalized on the basis of clinical parameters. Two models include several clinical patient characteristics and are therefore most suitable to evaluate personalized treatment, although some important clinical parameters are still missing.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Martine PhD, Talitha L. PhD, Yumi MSc, Andrew H. DPhil, Sixten MSc, Roberto W. MD, PhD, Ryan N. PharmD, PhD, Sven-Arne PhD, Reiner PhD, Nancy PhD, Yevgeniy MSc, Margarethe E. MSc, Maureen P.M.H. PhD,